Log in
NASDAQ:SBBP

Strongbridge Biopharma Stock Forecast, Price & News

$2.21
-0.02 (-0.90 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.18
Now: $2.21
$2.28
50-Day Range
$2.23
MA: $3.53
$4.24
52-Week Range
$1.43
Now: $2.21
$4.63
Volume1.01 million shs
Average Volume443,539 shs
Market Capitalization$120.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Read More
Strongbridge Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.71 million
Book Value$1.33 per share

Profitability

Net Income$-49,450,000.00
Net Margins-205.02%

Miscellaneous

Employees71
Market Cap$120.13 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$2.21
-0.02 (-0.90 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

How has Strongbridge Biopharma's stock been impacted by COVID-19?

Strongbridge Biopharma's stock was trading at $2.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SBBP shares have decreased by 4.7% and is now trading at $2.21.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Strongbridge Biopharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Strongbridge Biopharma
.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Strongbridge Biopharma
.

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) announced its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.08. The biotechnology company had revenue of $7.76 million for the quarter, compared to analyst estimates of $6.11 million. Strongbridge Biopharma had a negative return on equity of 80.86% and a negative net margin of 205.02%.
View Strongbridge Biopharma's earnings history
.

What guidance has Strongbridge Biopharma issued on next quarter's earnings?

Strongbridge Biopharma updated its FY 2020 Pre-Market earnings guidance on Tuesday, September, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $28-29 million, compared to the consensus revenue estimate of $27.68 million.

What price target have analysts set for SBBP?

5 brokerages have issued twelve-month price targets for Strongbridge Biopharma's stock. Their forecasts range from $5.00 to $18.00. On average, they expect Strongbridge Biopharma's share price to reach $9.13 in the next year. This suggests a possible upside of 312.9% from the stock's current price.
View analysts' price targets for Strongbridge Biopharma
.

Are investors shorting Strongbridge Biopharma?

Strongbridge Biopharma saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 826,300 shares, an increase of 13.0% from the August 15th total of 731,200 shares. Based on an average trading volume of 428,000 shares, the days-to-cover ratio is presently 1.9 days. Approximately 2.0% of the shares of the stock are sold short.
View Strongbridge Biopharma's Short Interest
.

Who are some of Strongbridge Biopharma's key competitors?

What other stocks do shareholders of Strongbridge Biopharma own?

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the following people:
  • Mr. John H. Johnson, Exec. Chairman (Age 62, Pay $765.19k)
  • Mr. Robert Matthew Lutz, Chief Financial Officer (Age 51, Pay $543.13k)
  • Mr. Richard S. Kollender CPA, M.B.A., CPA, Chief Operating Officer (Age 51, Pay $50.04k)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 55, Pay $593.89k)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Ikarian Capital LLC (6.02%), Hudson Bay Capital Management LP (2.23%), Russell Investments Group Ltd. (0.79%), Jacobs Levy Equity Management Inc. (0.60%), Knott David M (0.54%) and Nuveen Asset Management LLC (0.48%).
View institutional ownership trends for Strongbridge Biopharma
.

Which major investors are selling Strongbridge Biopharma stock?

SBBP stock was sold by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Ikarian Capital LLC, Bank of New York Mellon Corp, Algert Global LLC, and UBS Group AG.
View insider buying and selling activity for Strongbridge Biopharma
.

Which major investors are buying Strongbridge Biopharma stock?

SBBP stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Nuveen Asset Management LLC, Worth Venture Partners LLC, Jacobs Levy Equity Management Inc., Knott David M, Strs Ohio, Two Sigma Advisers LP, and First Quadrant L P CA.
View insider buying and selling activity for Strongbridge Biopharma
.

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.21.

How big of a company is Strongbridge Biopharma?

Strongbridge Biopharma has a market capitalization of $120.13 million and generates $21.71 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. Strongbridge Biopharma employs 71 workers across the globe.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is www.strongbridgebio.com.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.